C9 anticorps (FITC)

N° du produit ABIN1106799

Cet anticorps anti-C9 est un anticorps Souris Monoclonal détectant C9 dans IHC (p), IF, EIA, IHC (fro) et Func. Adapté pour Humain, Cheval et Porc.

Aperçu rapide pour C9 anticorps (FITC) (ABIN1106799)

Antigène: C9 (Complement Component C9 (C9))

Reactivité: Humain, Cheval, Porc

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp C9 est conjugé à/à la FITC

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunofluorescence (IF), Enzyme Immunoassay (EIA), Immunohistochemistry (Frozen Sections) (IHC (fro)), Functional Studies (Func)

Clone: AE11

Détail du produit anti-C9 anticorps (FITC)

Réactivité croisée (Details): Species reactivity (tested):Human, horse, pig

Purification: Protein G

Isotype: IgG2a

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Concentration: 0.1 mg/mL

Buffer: PBS, 0.02 % sodium azide, 0.1 % bovine serum albumin

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C

Stockage commentaire: Store at 2 - 8 °C.

Détails sur C9

Antigène: C9 (Complement Component C9 (C9))

Autre désignation: Complement C9

Sujet: The three distinct activation pathways of complement converge with the formation of a C5 convertase. The cleavage of C5 by this convertase initiates the lytic or terminal pathway. In contrast to the activation pathways, which require enzymatic cleavage for activation, the terminal pathway relies on conformational changes induced by binding. Binding of C6 facilitates binding of C7 which alters the conformation of the complex. After binding of C8, a variable number of C9 Molecules associate with the C5b678 complex, which is also termed the terminal complement complex (TCC). The formation of TCC causes lysis of cells or can trigger a variety of cellular metabolic pathways resulting in the synthesis and release of inflammatory mediators. The TCC contains neoantigens that are absent from the individual native components. C9 neoantigens are present both in the membrane-bound (MAC) and the fluid-phase (SC5b-9) complex. TCC is present in normal human plasma and increased in patients with complement activation.Synonyms: Complement 9, Complement component C9

UniProt: P02748

Pathways: Système du Complément